Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

BAP1, PBRM1, and metabolic pathway changes correlate with RCC subtype-specific survival

Ricketts C et al. Cell Reports April 2018, Pages 313–326.e5 https://doi.org/10.1016/j.celrep.2018.03.075

Key clinical point: Different histologically defined RCC subtypes are characterized by distinctive mutations, chromosomal copy number alterations, and expression patterns of mRNA, miRNA, and lncRNA. Histology plus genomics provide insight into patient-centered management. A tumor or liquid biopsy, provide invaluable information and prognostic biomarkers to guide clinical and surgical management.

Major finding: TP53 mutation correlated with decreased survival in clear cell RCC (p = 0.0002) and papillary RCC (p = 0.0049), while PTEN mutation correlated with decreased survival in chromophobe RCC (p = 0.0138). While BAP1 mutation correlated with decreased survival across the entire cohort (p = 0.0002) and within the clear cell RCC group (p = 0.0035), BAP1 mutation did not correlate with survival in papillary RCC or chromophobe RCC. Similarly, PBRM1 mutation, which has been shown to not correlate with survival in clear cell RCC, was found to correlate with decreased survival in papillary RCC (p = 0.0008) that was specific to type 1 papillary RCC (p < 0.0001).

Study details: 843 RCC from the three major histologic subtypes, including 488 clear cell RCC, 274 papillary RCC, and 81 chromophobe RCC were evaluated.

Disclosures: The authors had no relevant financial disclosures.

Source: Ricketts C et al. Cell Reports April 2018, Pages 313–326.e5 https://doi.org/10.1016/j.celrep.2018.03.075

Citation:

Ricketts C et al. Cell Reports April 2018, Pages 313–326.e5 https://doi.org/10.1016/j.celrep.2018.03.075

This Week's Must Reads

CMS freezing of risk adjustment payments predicted to drive up insurance premiums, United States District Court Ruling Puts Risk Adjustment On Hold

If confirmed as Supreme Court justice, Kavanaugh could upend ACA, Case references, including Seven-Sky v. Holder

Software boosts accuracy of colonoscopies, Tripathi PV et al. DDW 2018 (Digestive Disease Week, 2018). Presentation 133.

Proposed fee schedule for 2019 could cut EHR hours, https://s3.amazonaws.com/public-inspection.federalregister.gov/2018-14985.pdf

Must Reads in Renal Cell Carcinoma

EBUS-TBNA guides need for further treatment in RCC, Val-Bernal J et al. Pathology Research and Practice 2018; 214 (7), 949-56.

Clear cell papillary RCC distinguished by unique staining pattern, Wang Y et al. Annals of Diagnostic Pathology 36: 2018; 1-4. https://doi.org/10.1016/j.anndiagpath.2018.06.007

Myelodysplasia risk high in RCC patients, Shenoy N et al. Clinical Genitourinary Cancer, Published online June 28, 2018. https://doi.org/10.1016/j.clgc.2018.06.008

Pembrolizumab in advanced clear cell RCC, McDermott DF et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 4500.

Do docetaxel nanoparticles boost response in mCRPC?, Autio KA et al. JAMA Oncol. 2018 July 5. doi: 10.1001/jamaoncol.2018.2168.